AstraZeneca PLC (AZNCF)
| Previous Close | 134.13 |
| Open | 134.13 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 134.13 - 134.13 |
| 52 Week Range | 105.26 - 143.90 |
| Volume | |
| Avg. Volume | 2,653 |
| Market Cap | 207.833B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.85 (2.23%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | N/A |
- Zacks
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
- Zacks
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
- Motley Fool
Why Gilead Sciences Stock Was a 5% Winner Today
Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company had some good news to impart about an important cancer drug. Gilead announced that morning that its breast cancer treatment Trodelvy recorded "statistically significant and clinically meaningful" results in a phase 3 clinical trial.
